Healthcare Providers and Services
Company Overview of Aurora Diagnostics, LLC
Aurora Diagnostics, LLC, a specialized laboratory company, provides unsurpassed diagnostic, prognostic, and therapeutic information and services to physicians, hospital systems, and researchers in the United States. It offers pathology services, such as dermatopathology, gastrointestinal and hepatic pathology, hematopathology, and genitourinary; and pathology services to women’s health care providerpathology. The company also provides molecular diagnostic services that focus on pharmacogenomics, oncology, women’s health, and infectious diseases; and hospital-based clinical and management solutions, such as anatomic and clinical, professional component, and technical component pathology servi...
11025 RCA Center Drive
Palm Beach Gardens, FL 33410
Founded in 2006
Key Executives for Aurora Diagnostics, LLC
Chief Executive Officer and President
Executive Vice President of Sales & Marketing
Compensation as of Fiscal Year 2017.
Aurora Diagnostics, LLC Key Developments
Aurora Diagnostics Enters into a Seventh Amendment to Financing Agreement
Apr 25 17
On April 20, 2017, Aurora Diagnostics Holdings, LLC, as guarantor, its subsidiary Aurora Diagnostics, LLC, as borrower, and certain other subsidiaries of the Company, as guarantors, entered into a seventh amendment to the Financing Agreement, dated as of July 31, 2014 with Cerberus Business Finance, LLC, as administrative agent and collateral agent. The Seventh Amendment amended the definition of Final Maturity Date to modify the provision that accelerated the maturity date of the Financing Agreement to October 14, 2017 in the event that any of the Company's 10.750% Senior Notes due 2018 had not been refinanced prior to such date. As amended, the maturity of the Financing Agreement will be accelerated to October 14, 2017 only in the event that the maturity of more than $2.6 million in aggregate principal amount of Existing Notes has not been extended to October 31, 2019 or a later date on or before October 14, 2017. In addition, pursuant to the Seventh Amendment, the lenders thereunder consented to the Company redeeming, repurchasing or paying at maturity up to $2.6 million of Existing Notes at any time and from time to time within eight months of the consummation of the Company's Exchange Offer.
Aurora Diagnostics Holdings, LLC and Aurora Diagnostics, LLC Enters into Sixth Amendment to the Financing Agreement
Mar 31 17
On March 27, 2017, Aurora Diagnostics Holdings, LLC (the Company"), its subsidiary Aurora Diagnostics, LLC, as borrower, and certain other subsidiaries of the Company, as guarantors, entered into a sixth amendment to the Financing Agreement, dated as of July 31, 2014 (as amended, restated, supplemented or otherwise modified from time to time, the Financing Agreement") with Cerberus Business Finance, LLC, as administrative agent and collateral agent. The sixth amendment amends the definition of Permitted Acquisition" under the Financing Agreement to permit the company to consummate certain additional acquisitions upon the payment of a $225,000 consent fee. The sixth amendment provides a 60 day extension to the Company's obligation to deliver its audited financial statements for the year ended December 31, 2016 pursuant to the Financing Agreement. In connection with the extension, the sixth amendment provides that, beginning on April 1, 2017 until the date on which the financial statements have been delivered, the Applicable Margin shall increase to 7.125%, in the case of Reference Rate Loans, and 8.125%, in the case of LIBOR Rate Loans. The company intends to deliver its audited financial statements for the year ended December 31, 2016 on March 31, 2017, and therefore, does not expect an increase in the Applicable Margin.
Similar Private Companies By Industry
Recent Private Companies Transactions